Compare CAG & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAG | PTGX |
|---|---|---|
| Founded | 1919 | 2006 |
| Country | United States | United States |
| Employees | 17400 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 9.5B |
| IPO Year | 1994 | 2016 |
| Metric | CAG | PTGX |
|---|---|---|
| Price | $16.41 | $153.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | $16.88 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 10.3M | 448.6K |
| Earning Date | 04-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.84% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | ★ $1,500,000,000.00 | N/A |
| Revenue This Year | N/A | $874.25 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $64.12 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.53 | $56.56 |
| 52 Week High | $20.32 | $160.81 |
| Indicator | CAG | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 69.73 | 62.21 |
| Support Level | $15.96 | $94.48 |
| Resistance Level | $17.83 | N/A |
| Average True Range (ATR) | 0.40 | 4.92 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 94.41 | 74.71 |
Conagra Brands Inc is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). The majority of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, and Wish-Bone. The company sells through the USA retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.